Heart, Lung and Circulation
Volume 17, Issue 5 , Pages 364-369 , October 2008

Quantitative and Qualitative Changes in the Resting Electrocardiograph After Percutaneous Transluminal Septal Myocardial Ablation for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Received 1 November 2007 ,Revised 13 March 2008 ,Accepted 19 March 2008.

References 

  1. Flores-Ramirez R, Lakkis NM, Middleton KJ, Killip D, Spencer WH, Nagueh SF. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology. 2001;37(January (1)):208–214
  2. Roberts R, Sigwart U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy. Circulation. 2005;112(July (2)):293–296
  3. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346(July (8969)):211–214
  4. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998;98(October (17)):1750–1755
  5. Chang SM, Nagueh SF, Spencer WH, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. Journal of the American College of Cardiology. 2003;42(July (2)):296–300
  6. Qin JX, Shiota T, Lever HM, Asher CR, Popovic ZB, Greenberg NL, et al. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. American Journal of Cardiology. 2004;93(January (2)):171–175
  7. Runquist LH, Nielsen CD, Killip D, Gazes P, Spencer WH. Electrocardiographic findings after alcohol septal ablation therapy for obstructive hypertrophic cardiomyopathy. American Journal of Cardiology. 2002;90(November (9)):1020–1022
  8. Kovacic JC, Muller D. Hypertrophic cardiomyopathy: state-of-the-art review, with focus on the management of outflow obstruction. Internal Medicine Journal. 2003;33(November (11)):521–529
  9. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology. 2001;38(November (6)):1701–1706
  10. Spirito P, Maron BJ. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology. 1999;33(March (4)):1071–1075
  11. Riera AR, de Cano SJ, Cano MN, Gimenez VM, de Padua Fleury Neto LA, Sousa JE. Vector electrocardiographic alterations after percutaneous septal ablation in obstructive hypertrophic cardiomyopathy. Possible anatomic causes. Arquivos Brasileiros de Cardiologia. 2002;79(November (5)):466–475
  12. Kazmierczak J, Kornacewicz-Jach Z, Kisly M, Gil R, Wojtarowicz A. Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Heart. 1998;80(September (3)):257–262
  13. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. Journal of the American College of Cardiology. 2000;36(September (3)):852–855
  14. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98(December (22)):2415–2421
  15. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. European Heart Journal. 1999;20(September (18)):1342–1354
  16. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation. 1997;95(April (8)):2075–2081
  17. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. Journal of the American College of Cardiology. 1998;31(February (2)):252–258
  18. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart. 2000;83(March (3)):326–331
  19. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103(March (11)):1492–1496

PII: S1443-9506(08)00125-X

doi: 10.1016/j.hlc.2008.03.084

Heart, Lung and Circulation
Volume 17, Issue 5 , Pages 364-369 , October 2008

Article Tools

* Image Usage & Resolution